Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
05/2004
05/05/2004CN1148181C Use of flavnolignanes for the prepn. of medicaments with antiproliferative activity in uterus, ovary and breast
05/05/2004CN1148179C 20-Hete antagonists and agonists
05/04/2004US6730794 Substituted indolealkanoic acids
05/04/2004US6730695 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for V1b and V1a arginine-vasopressin receptors
05/04/2004US6730690 Delaying the onset or reducing the risk of developing atherosclerosis in a human patient comprising administering to said patient an effective amount of a compound of invention and an hmg-coa reductase inhibitor
05/04/2004US6730674 Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
05/04/2004US6730664 The side-effects of chemotherapy are suppressed or reduced
05/04/2004CA2296178C Human intestinal npt2b
05/04/2004CA2183234C Agent for prophylaxis and treatment of thromboxane a2-mediated diseases
05/04/2004CA2069600C Fatty acid compositions
04/2004
04/29/2004WO2004035581A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
04/29/2004WO2004035570A1 Large conductance calcium-activated k channel opener
04/29/2004WO2004035536A2 Azo compounds for type i phototherapy
04/29/2004WO2004019868A3 N-biarylmethyl aminocycloalkanecarboxamide derivatives
04/29/2004WO2003104255A3 Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives as ligands for the neuropeptide y5 receptor
04/29/2004WO2003086282A3 Nitric oxide donors, compositions and methods of use
04/29/2004WO2003082798A8 Natural compounds and derivatives thereof for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications
04/29/2004WO2003032913A9 Methods and compositions for targeting proteins across the blood brain barrier
04/29/2004WO2003009807A3 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
04/29/2004WO2003003972A3 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof
04/29/2004WO2003003004A3 Method for identifying compounds the specifically deplete mast cells
04/29/2004WO2002100417A8 Use of glycosaminoglycans for the treatment of hiv-associated nephropathy
04/29/2004WO2002079169A8 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
04/29/2004WO2002070669A3 Secreted proteins
04/29/2004WO2002018341A8 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors
04/29/2004US20040082805 Cytokine antagonist; immunology, viricides, antitumor agents, anticancer agents
04/29/2004US20040082787 Chemical compounds
04/29/2004US20040082781 Bicyclic nitrogenous fused-ring compound
04/29/2004US20040082666 Antiserotonine agents
04/29/2004US20040082661 Urea derivatives having vanilloid receptor (vr1) antagonist activity
04/29/2004US20040082658 Side-chain halogenated amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases
04/29/2004US20040082636 Method for the prophylaxis or treatment of glomerulonephritis
04/29/2004US20040082602 Kinase inhibitor; analgesics; antiarthritic agents; antihistamines; gastrointestinal disorders
04/29/2004US20040082595 Antiproliferative agents; antitumor agents; cyclin-dependent kinase inhibitor
04/29/2004US20040082589 Quinoline derivatives as nk-3 and nk-2 antagonists
04/29/2004US20040082584 Antiinflammatory agents; antihistamines; skin disorders; antiarthritic agents; antidiabetic agents; autoimmune disease
04/29/2004US20040082575 Compounds and methods for modulation of estrogen receptors
04/29/2004US20040082569 Novel substituted amides, their preparation and use
04/29/2004US20040082566 Pyrrolidine sulfonamides
04/29/2004US20040082556 Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use
04/29/2004US20040082551 Novel pyrazoles and their use as p38 kinase inhibitors
04/29/2004US20040082548 Cardiovascular disorders; Alzheimer's disease; anticholesterol agents
04/29/2004US20040082542 Useful as modulators of interaction between receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, beta-amyloid and amphoterin
04/29/2004US20040082506 For treating hypophosphatemic rickets/osteomalacia/ osteoporosis/renal osteodystrophy/dialysis-associated bone diseases
04/29/2004US20040082064 Stimulanting immunology response; calibrating success of organ, tissue transplant; polymerase chain reaction analysis; administering immunosuppressants
04/29/2004US20040081972 Detecting antibodies; screening, development therapies for infections, inflammation; polypeptides; monoclonal antibodies
04/29/2004US20040081971 Gastrointestinal disorders; cardiovascular disorders; autoimmune diseases; cell proliferation; antiinflammatory agents
04/29/2004US20040081715 Cholesterol reducing confectionery comprising a cocoa procyanidin monomer and/or oligomer and a sterol and/or stanol based cholesterol lowering agent
04/29/2004US20040081673 Compositions and methods for the treatment of skin damage
04/29/2004CA2502211A1 Azo compounds for type i phototherapy
04/29/2004CA2501979A1 Large conductance calcium-activated k channel opener
04/28/2004EP1413305A1 Aryl (or heteroaryl) azolylcarbynol derivatives for the treatment of urinary incontinence
04/28/2004EP1413116A1 Access control system
04/28/2004EP1412363A1 Gonadotropin-releasing hormone receptor antagonists
04/28/2004EP1412361A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists
04/28/2004EP1412357A1 Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
04/28/2004EP1412354A1 DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A 2a? RECEPTOR AND THEIR USE AS MEDICAMENTS
04/28/2004EP1412338A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
04/28/2004EP1412330A1 Piperidine derivatives useful as modulators of chemokine receptor activity
04/28/2004EP1412327A2 Inhibitors of protein kinase for the treatment of disease
04/28/2004EP1411947A2 Salts of substituted 1, 2, 3, 4-tetrahydroisoquinoline-2-carboxylic acid derivatives
04/28/2004EP1411945A1 Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists
04/28/2004EP1411941A2 Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
04/28/2004EP1411898A1 Pharmaceutical composition comprising lipids with a polar and a nonpolar moiety
04/28/2004EP1411881A2 5HT sb 2C /sb RECEPTOR MODULATORS
04/28/2004EP1411880A2 Recombinant vsv for the treatment of tumor cells
04/28/2004CN1492872A Tricycle quinolinone and tricycle quinoline as androgen receptor modulator compounds
04/28/2004CN1492869A Tricyclic androgen receptor modulator compounds and method
04/28/2004CN1492868A Quinuclidine carbamate derivatives and their use as m3 antigonists
04/28/2004CN1491719A Use of cicade flower in preparing medicine for treating chronic renal failure
04/28/2004CN1491717A Chinese medicine composition for treating primary glomerulopathy and its preparing method
04/28/2004CN1491708A Nephritis soft capsule and its preparing method
04/28/2004CN1491644A Fibrauretine slow releasing prepn
04/28/2004CN1147584C Modulators of tissue regeneration
04/28/2004CN1147471C Renin inhibitors
04/28/2004CN1147461C 3-amino-3-aryl-1-alcohol derivatives and preparation and use thereof
04/28/2004CN1147317C Combination of tyrosine kinase inhibitor and chemical castration and its use in pharmaceutical production
04/27/2004US6727353 Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain
04/27/2004US6727275 Pyrrolidinone derivatives
04/27/2004US6727258 Allosteric adenosine receptor modulators
04/27/2004US6727257 Hypotensive agents for intraocular pressure; anticholesterol agents; relaxing urinary tract tissue; benign prostatic hyperplasia, impotency, and cardiovascular disorders; antiarrhythmia agents
04/27/2004US6727255 Brain, nervous system and psychological disorders
04/27/2004US6727251 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease
04/27/2004US6727239 Inhibitory activity on no- synthase enzymes producing nitrogen monoxide no and/or an activity which traps the reactive oxygen species (ros)
04/27/2004CA2317530C Dysuria remedies
04/22/2004WO2004033687A1 Method of screening remedy for renal failure
04/22/2004WO2004033681A1 Substance having activity of promoting platelet aggregation
04/22/2004WO2004033457A1 Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group
04/22/2004WO2004020430A3 Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics
04/22/2004WO2004018431A3 Novel phenanthridines
04/22/2004WO2004010945A3 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use
04/22/2004WO2004009784A3 Novel inhibitors of kinases
04/22/2004WO2004005544A3 Marker genes for determining renal toxicity
04/22/2004WO2003101958A3 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors
04/22/2004WO2002074767A8 Metalloproteinase inhibitors
04/22/2004WO2002074748A8 Metalloproteinase inhibitors
04/22/2004US20040077896 Compounds for the treatment of metabolic disorders
04/22/2004US20040077877 Jun n-terminal kinase inhibitors
04/22/2004US20040077858 Making 4-(1H-indol-5-yloxy)-pyrrolo(2,1-f)(1,2,4)triazine compounds that are tyrosine kinase inhibitors; reducing vascular permeability; anticancer agents
04/22/2004US20040077854 4-chloro-N-((5-((4-(hexylamino)piperidin-1-yl)sulfonyl)thien-2 -yl)methyl)benzamide for example; JUN kinase inhibitors to treat nervous system disorders, cancer, cardiovascular and autoimmune disorders